8Z-3,4',5-Trimethoxystilbene

8Z-3,4',5-Trimethoxystilbene

SCHEMBL1006207

COc1ccc(/C=C\c2cc(OC)cc(OC)c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 6/20 1.00
CYP1B1 Q16678 6/20 1.00
ESR1 P03372 4/20 1.00
NQO2 P16083 4/20 1.00
PTGS2 P35354 3/20 1.00
AHR P35869 3/20 1.00
CYP1A2 P05177 3/20 1.00
ABL1 P00519 2/20 1.00
TTR P02766 2/20 1.00
ABCB1 P08183 2/20 1.00
ALOX5 P09917 2/20 1.00
BCR P11274 2/20 1.00
CYP19A1 P11511 2/20 1.00
TUBB1 Q9H4B7 2/20 1.00
TUBB4A P04350 1/20 1.00
TUBB P07437 1/20 1.00
TUBA3C P0DPH7 1/20 1.00
TUBA1B P68363 1/20 1.00
TUBA4A P68366 1/20 1.00
TUBB4B P68371 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trismethoxyresveratrol SCHEMBL918739 1.00 CYP1A1 (1.00) CYP1A1CYP1B1ESR1NQO2PTGS2
Trismethoxyresveratrol SCHEMBL918740 1.00 CYP1A1 (1.00) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL13443549 0.95 CYP1A1 (0.91) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL3758141 0.95 CYP1A1 (0.91) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL5809462 0.91 CYP1A1 (0.84) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL5809455 0.91 CYP1A1 (0.84) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL9177232 0.91 TUBB1 (0.83) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL13790336 0.88 RELA (0.81) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL1743365 0.88 CYP1A1 (1.00) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL4881152 0.88 RELA (0.81) CYP1A1CYP1B1ESR1NQO2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859615-B2 Compounds, compositions and methods for reducing toxicity and treating or preventing diseases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-10-14 US claimed
CN-102215840-B Compounds, compositions and methods for reducing toxicity and treating or preventing diseases THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-10-08 CN claimed
US-20120178704-A1 PREVENTION AND TREATMENT OF COLON CANCER RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2012-07-12 US claimed
US-20110312904-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2011-12-22 US claimed
EP-2331093-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES The Trustees of Columbia University in the City of New York (US) 2011-06-15 EP claimed
US-20110124690-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2011-05-26 US claimed
WO-2010025272-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2010-03-04 WO claimed
WO-2009105123-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2009-08-27 WO claimed
WO-2008103916-A2 COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (US) 2008-08-28 WO claimed
WO-2008070872-A1 PREVENTION AND TREATMENT OF COLON CANCER RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2008-06-12 WO claimed
WO-2003031381-A2 SYNTHESIS OF (Z)-3,5,4'-TRIMETHOXYSTILBENE, AND USE THEREOF UNIVERSITE LOUIS PASTEUR (FR) 2003-04-17 WO claimed
US-12404221-B2 Methods of arene alkenylation UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2025-09-02 US disclosed
US-20250127890-A1 COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTIOUS DISEASE-19 (COVID-19) THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) 2025-04-24 US disclosed
US-20250084103-A1 COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-03-13 US disclosed
US-12180228-B2 Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-12-31 US disclosed
WO-2003031381-A2 SYNTHESIS OF (Z)-3,5,4'-TRIMETHOXYSTILBENE, AND USE THEREOF UNIVERSITE LOUIS PASTEUR (FR) 2003-04-17 WO disclosed
WO-2003031381-A2 SYNTHESIS OF (Z)-3,5,4'-TRIMETHOXYSTILBENE, AND USE THEREOF UNIVERSITE LOUIS PASTEUR (FR) 2003-04-17 WO disclosed
WO-2003031381-A2 SYNTHESIS OF (Z)-3,5,4'-TRIMETHOXYSTILBENE, AND USE THEREOF UNIVERSITE LOUIS PASTEUR (FR) 2003-04-17 WO disclosed
US-5430062-A Combretastatin analogues; inhibition of tubulin polymerization and colchicine binding; antitumor,-mitotic and -neoplastic agents RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1995-07-04 US disclosed
WO-1993023357-A1 STILBENE DERIVATIVES AS ANTICANCER AGENTS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312904-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES TUBA1C, TUBB1, TOP1 CYP1A1 1266/4885CYP1B1 1897/4885ESR1 4109/4885
US-20120178704-A1 PREVENTION AND TREATMENT OF COLON CANCER APC, SI, NFKBIA CYP1A1 1123/4885CYP1B1 1133/4885ESR1 2698/4885
US-20250084103-A1 COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF DNPEP, DHPS, NPEPPS CYP1A1 832/4885CYP1B1 248/4885ESR1 2013/4885
US-12404221-B2 Methods of arene alkenylation CYBB, CBR3, AHR CYP1A1 90/4885CYP1B1 62/4885ESR1 179/4885
US-20110124690-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER BDNF, NGF, NTRK2 CYP1A1 4875/4885CYP1B1 4861/4885ESR1 4561/4885
US-12180228-B2 Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof DNPEP, DHPS, NPEPPS CYP1A1 832/4885CYP1B1 248/4885ESR1 2013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.